#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Residual inflammatory cardiovascular risk – diagnostic and therapeutic challenge


Authors: Ján Murín 1;  Jozef Bulas 1;  Martin Wawruch 2;  Udovít Gašpar 1,3
Authors‘ workplace: I. Interná klinika LF UK a UNB, Bratislava 1;  Ústav farmakológie a klinickej farmakológie LF UK, Bratislava 2;  Fakulta zdravotníckych vied Univerzity sv. Cyrila a Metoda v Trnave 3
Published in: AtheroRev 2021; 6(2): 95-98
Category: Reviews

Overview

Ischemic heart disease (IHD) is the most important disease concerning the highest mortality and morbidity among diseases in the world. We try to prevent this disease by modification of lifestyle and by treatment of traditional cardiovascular risk factors. This is nowadays not enough. Vascular inflammation seems to be a new critical factor of atherosclerotic plaque development and contributes also to plaque instability. The are some new possibilities to diagnose the presence of vascular inflammation: by serum hsCRP biomarker, by PET/CT and PET/MR examinations, by CT coronary calcium score or by CT FAI index (of changes in perivascular fat tissue around coronary arteries). If there is a presence of vascular inflammation in coronary arteries, then we should try to block it by antiinflammatory drugs (colchicin, canakinumab), because there is evidence to improve the prognosis of cardiovascular patients.

Keywords:

antiinflammatory treatment – cardiovascular events – residual inflammatory vascular risk


Sources

1. Timmis A, Townsend N, Gale C et al. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J 2018; 39(7): 508–579. Dostupné z DOI: .

2. Piepoli MF, Hoes AW, Agewall S et al. [ESC Scientific Document Group]. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACRP). Eur Heart J 2016; 37(39): 2315–2381. Dostupné z DOI: .

3. Montalescot G, Sechtem U, Achenbach S et al. [Task Force Members] 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949–3003. Dostupné z DOI: .

4. Catapano AL, Graham I, De Backer G et al. [ESC Scientific Document Group]. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058. Dostupné z DOI: .

5. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340(2): 115–126. Dostupné z DOI: .

6. Ridker PM, Everett BM, Thuren T et al. [CANTOS Trial Group]. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377(12): 1119–1131. .

7. Antonopoulos AS, Sanna F, Sabharwal N et al. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med 2017; 9(398): eaal2658. Dostupné z DOI: .

8. Oikonomou EK, Marwan M, Desai MY et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet 2018; 392(10151): 929–939. Dostupné z DOI: .

9. Tousoulis D, Psarros C, Demosthenous M et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 2014; 63(23): 2491–2502. Dostupné z DOI: .

10. Alfakry H, Malle E, Koyani CN et al. Neutrophil proteolytic activation cascades: a possible mechanistic link between chronic periodontitis and coronary heart disease. Innate Immun 2016; 22(1): 85–99. Dostupné z DOI: .

11. Antoniades C, Bakogiannis C, Tousoulis D et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54(8): 669–677. Dostupné z DOI: .

12. Mašlanková J, Stupák M, Birková A et al. Úloha matrixových metaloproteináz v procese iniciácie a rozvoja aterosklerózy. Ateroskleróza 2019; XXIII(3–4): 1375–1379. Dostupné z WWW: .

13. Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res 2017; 113(9): 1074–1086. Dostupné z DOI: .

14. Takaoka M, Suzuki H, Shioda S et al. Endovascula injury induces rapid phenotypic changes in perivascular adipose tissue. Arterioscler Thromb Vasc Biol 2010; 30(8): 1576–1582. Dostupné z DOI: .

15. Vacca M, Di Eusanio M, Cariello M et al. Integrative miRNA and whole- genome analyses of epicardial adipose tissue in patients with coronary atherosclerosis. Cardiovasc Res 2016; 109(2): 228–239. Dostupné z DOI: .

16. Ohyama K, Matsumoto Y, Amamizu H et al. Association of coronary perivascular adipose tissue inflammation and drug-eluting stent-induced coronary hyperconstricting responses in pigs: (18)F-fluorodeoxyglucose positron emission tomography imaging study. Arterioscler Thromb Vasc Biol 2017; 37(9): 1757–1764. Dostupné z DOI: .

17. Ridker PM, Everett BM, Pradhan A et al. [JUPITTER Study Group]. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195–2207. Dostupné z DOI: .

18. Ridker PM. How common is residual inflammatory risk? Circ Res 2017; 120(4): 617–619. Dostupné z DOI: .

19. Held C, White HD, Stewart RAH et al. [STABILITY Investigators]. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. J Am Heart Assoc 2017; 6(10): e005077. Dostupné z DOI: .

20. Pedicino D, Severino A, Ucci S et al. Epicardial adipose tissue microbial colonization and inflammasome activation in acute coronary syndrome. Int J Cardiol 2017; 236: 95–99. Dostupné z DOI: .

21. Duivenvoorde R, Mani V, Woodward M et al. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. JACC Cardiovasc Imaging 2013; 6(10): 1087–1094. Dostupné z DOI: .

22. Figueroa AL, Abdelbaky A, Truong QA et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging 2013; 6(12): 1250–1259. Dostupné z DOI: .

23. Newby DE, Adamson PD, Berry et al. [SCOT-HEART Investigators]. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med 2018; 379(10): 924–933. Dostupné z DOI: .

24. Ferencik M, Mayrhofer T, Bittner DO et al. Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the PROMISE randomized clinical trial. JAMA Cardiol 2018; 3(2):144–152. Dostupné z DOI: .

25. Otsuka K, Fukuda S, Tanaka A et al. Prognosis of vulnerable plaque on computed tomographic coronary angiography with normal myocardial perfusion image. Eur Heart J Cardiovasc Imaging 2014; 15(3): 332–340. Dostupné z DOI: .

26. Hou ZH, Lu B, Gao Y et al. Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc Imaging 2012; 5(10): 990–999. Dostupné z DOI: .

Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#